AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018

Feb 28, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-02-26

Reporting Person: Foster-Cheek Kaye I (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-26	Common stock	M	2200	$47.33	Acquired	2200	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-26	Stock option (right to buy)	$47.33	M	2200	Disposed	2026-06-20	Common stock (2200)	Direct

Footnotes

F1: This option was granted on June 21, 2016. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2017.